Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 31, Issue 39
  5. Article
Volume 31, Issue 39
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are FDA-approved drugs recommended for high-risk patients with LDL-cholesterol (LDL-c) levels ≥ 70 mg/dl. Several studies have also investigated the relationship between PCSK9 and periodontitis. Specifically, studies have investigated the association between periodontitis and periodontal PCSK9 levels in humans, and periodontium status in PCSK9-knockout wild-type mice. While a positive association between periodontitis and periodontal PCSK9 levels has been noted, the findings on the comparison of periodontium status between PCSK9-knockout and wild-type mice have been inconsistent. Different methodologies among these studies may explain this discrepancy. Future experimental studies on the impact of pharmacological PCSK9 inhibition on periodontal status as well as observational studies comparing periodontium status between patients receiving PCSK9 inhibitors and those receiving other lipid-lowering drugs will shed light on the role of PCSK9 in periodontal health and disease.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867331666230809100021
2023-09-27
2025-01-15

  • From This Site

    /content/journals/cmc/10.2174/0929867331666230809100021
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RosensonR.S. HegeleR.A. FazioS. CannonC.P. The evolving future of PCSK9 inhibitors.J. Am. Coll. Cardiol.201872331432910.1016/j.jacc.2018.04.05430012326
     [Google Scholar]
  2. JiaX. Al RifaiM. SaeedA. BallantyneC.M. ViraniS.S. PCSK9 inhibitors in the management of cardiovascular risk: A practical guidance.Vasc. Health Risk Manag.20221855556610.2147/VHRM.S27573935898405
     [Google Scholar]
  3. SahebkarA. WattsG.F. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes.Clin. Ther.20133581082109810.1016/j.clinthera.2013.06.01923932550
     [Google Scholar]
  4. ZijlstraL.E. MooijaartS.P. JukemaJ.W. PCSK9 inhibition in high-risk patients.Aging.20191123107911079210.18632/aging.10262131829977
     [Google Scholar]
  5. CesaroA. BianconiV. GragnanoF. MoscarellaE. FimianiF. MondaE. ScudieroO. LimongelliG. PirroM. CalabròP. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Biofactors.202046336738010.1002/biof.161931999032
     [Google Scholar]
  6. MacchiC. FerriN. SirtoriC.R. CorsiniA. BanachM. RuscicaM. Proprotein convertase subtilisin/kexin type 9.Am. J. Pathol.202119181385139710.1016/j.ajpath.2021.04.01634019847
     [Google Scholar]
  7. JamialahmadiT. PanahiY. SafarpourM.A. GanjaliS. ChahabiM. ReinerZ. SolgiS. Vahedian-azimiA. KianpourP. BanachM. SahebkarA. Association of serum PCSK9 levels with antibiotic resistance and severity of disease in patients with bacterial infections admitted to intensive care units.J. Clin. Med.2019810174210.3390/jcm810174231635200
     [Google Scholar]
  8. MahboobniaK. PirroM. MariniE. GrignaniF. BezsonovE.E. JamialahmadiT. SahebkarA. PCSK9 and cancer: Rethinking the link.Biomed. Pharmacother.202114011175810.1016/j.biopha.2021.11175834058443
     [Google Scholar]
  9. Momtazi-BorojeniA.A. Sabouri-RadS. GottoA.M.Jr PirroM. BanachM. AwanZ. BarretoG.E. SahebkarA. PCSK9 and inflammation: A review of experimental and clinical evidence.Eur. Heart J. Cardiovasc. Pharmacother.20195423724510.1093/ehjcvp/pvz02231236571
     [Google Scholar]
  10. KassebaumN.J. BernabéE. DahiyaM. BhandariB. MurrayC.J.L. MarcenesW. Global burden of severe periodontitis in 1990-2010: A systematic review and meta-regression.J. Dent. Res.201493111045105310.1177/002203451455249125261053
     [Google Scholar]
  11. ThermosG. TosiosK.I. Gingival ischemia and petechiae in a patient medicated with PCSK9 inhibitor for hypercholesterolemia: An adverse drug event?Clinic. Adv. Periodontics.201991202310.1002/cap.1004331490035
     [Google Scholar]
  12. TabetaK. HosojimaM. NakajimaM. MiyauchiS. MiyazawaH. TakahashiN. MatsudaY. SugitaN. KomatsuY. SatoK. IshikawaT. AkiishiK. YamazakiK. KatoK. SaitoA. YoshieH. Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey.J. Periodontal Res.201853344645610.1111/jre.1253329516504
     [Google Scholar]
  13. RughwaniR.R. CholanP.K. VictorD.J. IlangoP. CherianS.M. RughwaniR.N. TadepalliA. Evaluation of serum and salivary PCSK9 and IL6 and its association with periodontal inflammation and atherosclerotic cardiovascular diseases.J. Oral Biol. Craniofac. Res.202212563363810.1016/j.jobcr.2022.08.01336042970
     [Google Scholar]
  14. Yokoji-TakeuchiM. TabetaK. TakahashiN. ArimatsuK. MiyazawaH. Matsuda-MatsukawaY. SatoK. YamadaM. YamazakiK. Indirect regulation of PCSK9 gene in inflammatory response by Porphyromonas gingivalis infection.Heliyon.201951e0111110.1016/j.heliyon.2018.e0111130671557
     [Google Scholar]
  15. MiyazawaH. HondaT. MiyauchiS. DomonH. OkuiT. NakajimaT. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration.Clin Chim Acta.20124131-215415910.1016/j.cca.2011.09.023
     [Google Scholar]
  16. MiyazawaH. TabetaK. MiyauchiS. Aoki-NonakaY. DomonH. HondaT. NakajimaT. YamazakiK. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.Lipids Health Dis.201211112110.1186/1476‑511X‑11‑12122992388
     [Google Scholar]
  17. SunH.L. WuY.R. SongF.F. GanJ. HuangL.Y. ZhangL. HuangC. Role of PCSK9 in the development of mouse periodontitis before and after treatment: A double-edged sword.J. Infect. Dis.2018217466768010.1093/infdis/jix57429294034
     [Google Scholar]
  18. HuangL. WuH. WuY. SongF. ZhangL. LiZ. SunH. HuangC. Pcsk9 knockout aggravated experimental apical periodontitis via LDLR.J. Dent. Res.20221011839210.1177/0022034521101512834036816
     [Google Scholar]
  19. BaumeisterS.E. HoltfreterB. ReckelkammS.L. KocherT. AlayashZ. EhmkeB. Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis.J. Clin. Periodontol.202250111412036054135
     [Google Scholar]
  20. YuanY. WuW. SunS. ZhangY. ChenZ. PCSK9: A potential therapeutic target for sepsis.J. Immunol. Res.202020201810.1155/2020/268769233123601
     [Google Scholar]
/content/journals/cmc/10.2174/0929867331666230809100021
Loading
Roles of PCSK9 in the Pathogenesis of Periodontal Disease
Curr. Med. Chem. 31, 6429 (2024); https://doi.org/10.2174/0929867331666230809100021
/content/journals/cmc/10.2174/0929867331666230809100021
/content/journals/cmc/10.2174/0929867331666230809100021
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): inflammation; oral health; PCSK9; periodontal; periodontitis; periodontium

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test